Prognostic Value of Neutrophil Lymphocyte Ratio in Second Line Advanced Malignant Pleural Mesothelioma
Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=47102#.VGGJR2fHRK0
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=47102#.VGGJR2fHRK0
Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Background:
Malignant pleural mesothelioma is a lethal disease and hence the strong need for
identifying new prognostic factors. Methods: This is a retrospective study
including all eligible patients with advanced malignant pleural mesothelioma
(MPM) presenting to National Cancer Institute, Cairo University. Neutrophil
lymphocyte (N/L) ratio was assessed before second line chemotherapy. 2.5 was
used as the cutoff point. Endpoints were the assessment of correlation between
N/L ratio and clinical response (CR), progression free survival (PFS) and
overall survival (OS). Results: 52 patients (19 stage III and 33 stage IV) MPM
were included and followed up during the period from July 2009 till November
2012 with a median follow-up period of 2.6 months. 87.5% of patients with N/L
ratio > 2.5 showed progressive disease versus 91.7% in patients with N/L
ratio < 2.5 (P-value = 0.66). 6-month PFS was 11% for patients with N/L
ratio > 2.5 versus 14% for patients with N/L ratio < 2.5 (P-value = 0.001).
6-month OS was 72% for patients with N/L ratio > 2.5 versus 66% for patients
with N/L ratio < 2.5 (P-value = 0.4). Conclusion: N/L ratio is a potential
prognostic marker for advanced MPM treated with second line chemotherapy.
KEYWORDS
Cite this paper
El Bastawisy, A. , Yahia, M. , Rahman, A. and
Gaafar, R. (2014) Prognostic Value of Neutrophil Lymphocyte Ratio in
Second Line Advanced Malignant Pleural Mesothelioma. Journal of Cancer Therapy, 5, 717-722. doi: 10.4236/jct.2014.57080.
| [1] | Price, B. and Ware, A. (2009) Time Trend of Mesothelioma Incidence in the United States and Projection of Future Cases: An Update Based on SEER Data for 1973 through 2005. Critical Reviews in Toxicology, 39, 576-588. http://dx.doi.org/10.1080/10408440903044928 |
| [2] |
Pelucchi, C., Malvezzi, M., La
Vecchia, C., et al. (2004) The Mesothelioma Epidemic in Western Europe:
An Update. British Journal of Cancer, 90, 1022-1024. http://dx.doi.org/10.1038/sj.bjc.6601638 |
| [3] | Curran, D., Sahmoud, T., Therasse, P., van Meerbeeck, J., Postmus, P.E. and Giaccone, G. (1998) Prognostic Factors in Patients with Pleural Mesothelioma: The European Organization for Research and Treatment of Cancer Experience. Journal of Clinical Oncology, 16, 145-152. |
| [4] |
Herndon, J.E., Green, M.R.,
Chahinian, A.P., Corson, J.M., Suzuki, Y. and Vogelzang, N.J. (1998)
Factors Predictive of Survival among 337 Patients with Mesothelioma
Treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest,
113, 723-731. http://dx.doi.org/10.1378/chest.113.3.723 |
| [5] |
Wang, X. (2014) Neutrophil to
Lymphocyte Ratio in Relation to Risk of All-Cause Mortality and
Cardiovascular Events among Patients Undergoing Angiography or Cardiac
Revascularization: A Meta-Analysis of Observational Studies.
Atherosclerosis, 234, 206-213. http://dx.doi.org/10.1016/j.atherosclerosis.2014.03.003 |
| [6] | Wang, J. (2014) The Clinical Significance of Tumor-Infiltrating Neutrophils and Neutrophil-to-CD8+ Lymphocyte Ratio in Patients with Resectable Esophageal Squamous Cell Carcinoma. Journal of Translational Medicine, 12, 7. http://dx.doi.org/10.1186/1479-5876-12-7 |
| [7] |
Xue, P. (2014)
Neutrophil-to-Lymphocyte Ratio for Predicting Palliative Chemotherapy
Outcomes in Advanced Pancreatic Cancer Patients. Cancer Medicine, 3,
406-415. http://dx.doi.org/10.1002/cam4.204 |
| [8] | Jarnicki, A., Putoczki, T. and Ernst, M. (2010) Stat3: Linking Inflammation to Epithelial Cancer—More than a “Gut” Felling? Cell Division, 5, 14. http://dx.doi.org/10.1186/1747-1028-5-14 |
| [9] | Byrne, M.J. and Nowak, A.K. (2004) Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma. Annals of Oncology, 15, 257-260. http://dx.doi.org/10.1093/annonc/mdh059 |
| [10] |
Kao, S., Pavlakis, N., Harvie,
R., Vardy, J., Boyer, M., van Zandwijk, N. and Clarke, S. (2010) High
Blood Neutrophilto-Lymphocyte Ratio Is an Indicator of Poor Prognosis in
Malignant Mesothelioma Patients Undergoing Systemic Therapy. Clinical
Cancer Research, 16, 5805-5813. http://dx.doi.org/10.1158/1078-0432.CCR-10-2245 |
| [11] |
Sarraf, K.M., Belcher, E.,
Raevsky, F., Nicholson, A.G., Goldstraw, P. and Lim, E. (2009)
Neutrophil/Lymphocyte Ratio and Its Association with Survival after
Complete Resection in Non-Small Cell Lung Cancer. Journal of Thoracic
and Cardiovascular Surgery, 137, 425-428. http://dx.doi.org/10.1016/j.jtcvs.2008.05.046 |
| [12] |
Walsh, S.R., Cook, E.J.,
Goulder, F., Justin, T.A. and Keeling, N.J. (2005) Neutrophil-Lymphocyte
Ratio as a Prognostic Factor in Colorectal Cancer. Journal of Surgical
Oncology, 91, 181-184. http://dx.doi.org/10.1002/jso.20329 |
| [13] |
Kishi, Y., Kopetz, S., Chun, Y.,
Palavecino, M., Abdalla, E.K. and Vauthey, J.N. (2009) Blood
Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with
Colorectal Liver Metastases Treated with Systemic Chemotherapy. Annals
of Surgical Oncology, 16, 614-622. http://dx.doi.org/10.1245/s10434-008-0267-6 |
| [14] |
Halazun, K.J., Aldoori, A.,
Malik, H.Z., Al-Mukhtar, A., Prasad, K.R., Toogood, G.J., et al. (2008)
Elevated Preoperative Neutrophil to Lymphocyte Ratio Predicts Survival
Following Hepatic Resection for Colorectal Liver Metastases. European
Journal of Surgical Oncology, 34, 55-60. http://dx.doi.org/10.1016/j.ejso.2007.02.014 |
| [15] | Gomez, D., Morris-Stiff, G., Toogood, G., Lodge, J.P. and Prasad, K.R. (2008) Impact of Systemic Inflammation on Outcome Following Resection for Intrahepatic Cholangiocarcinoma. Journal of Surgical Oncology, 97, 513-518. http://dx.doi.org/10.1002/jso.21001 |
| [16] | Meniawy, T., Creaney, J., Lake, R. and Nowak, A. (2013) Existing Models, but Not Neutrophil-to-Lymphocyte Ratio, Are Prognostic in Malignant Mesothelioma. British Journal of Cancer, 109, 1813-1820. http://dx.doi.org/10.1038/bjc.2013.504 eww141111lx |
| [17] | Pinato, D., Stavraka, C., Flynn, M., Forster, M., O’Cathail, S., Seckl, M., Kristeleit, R., Olmos, D., Turnbull, S. and Blagden, S. (2014) An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials. PLoS ONE, 9, Article ID: e83279. http://dx.doi.org/10.1371/journal.pone.0083279 |
评论
发表评论